Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer

This study tests a three-drug combination — fruquintinib (an anti-blood vessel growth drug), camrelizumab (an immunotherapy drug), and capecitabine (an oral chemotherapy) — as a second-line treatment for patients with advanced colorectal cancer whose disease progressed on a standard chemotherapy regimen called FOLFOXIRI. **You may be eligible if...** - You have advanced colorectal cancer confirmed by biopsy that cannot be surgically removed - Your cancer progressed on or you could not tolerate a first-line chemotherapy regimen containing irinotecan, oxaliplatin, and fluorouracil (FOLFOXIRI) - You are 18 years or older with reasonable overall health (ECOG score 0–2) - You have at least one measurable tumor on imaging - Your blood counts, liver, and kidney function are adequate - Your estimated life expectancy is at least 12 weeks **You may NOT be eligible if...** - You have had anti-cancer treatment within the last 28 days - You have untreated or symptomatic brain metastases - You have serious heart disease, uncontrolled blood pressure, recent blood clots, or a history of gastrointestinal perforation or major bleeding - You have an autoimmune disease or are on immune-suppressing medications - You have active HIV, hepatitis, or another immune deficiency - You have received a live vaccine in the last 28 days - You are pregnant or breastfeeding - You have previously received fruquintinib Talk to your doctor to see if this trial is right for you.